English
DLL4, Fc Fusion, Avi-Tag Recombinant
DLL4, Fc Fusion, Avi-Tag Recombinant
Artikelnummer
BPS101903-1
Verpackungseinheit
10 µg
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Applications: Useful to study the binding of DLL4 in ELISA and in cellular assays.
Background: DLL4, or delta-like canonical Notch ligand 4, is part of the Notch signaling pathway and it is involved in normal tissue development and homeostasis. It is an agonist ligand and can bind to the four Notch receptors. It is expressed in the vascular system and plays a crucial role in angiogenesis. Loss of function of DLL4 results in VEGF upregulation, and the formation of immature vessels without a lumen. It has been shown that DLL4 inhibition can actually result in tumor regression by its role on VEGF upregulation. DLL4 is found in several tumor types, and it is found in tumor stem cells. Inhibition of DLL4 can thus contribute to cancer therapy via its several mechanisms of action.
Description: Recombinant human DLL4 (delta-like canonical Notch ligand 4), encompassing amino acids 27-529. This construct contains the Fc region of human IgG1 on the C-terminus, followed by an Avi-Tag™. This protein was affinity purified.
Format: Aqueous buffer solution.
Formulation: 8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
Genbank: NM_019074.4
Host Cell Line: HEK293
Purity: ≥90%
Storage Stability: At least 6 months at -80°C.
Tags: C-terminal Avi-Tag™
Uniprot: Q9NR61
Warnings: Avoid freeze/thaw cycles
Biosafety Level: Not applicable (BSL-1)
Applications: Useful to study the binding of DLL4 in ELISA and in cellular assays.
Background: DLL4, or delta-like canonical Notch ligand 4, is part of the Notch signaling pathway and it is involved in normal tissue development and homeostasis. It is an agonist ligand and can bind to the four Notch receptors. It is expressed in the vascular system and plays a crucial role in angiogenesis. Loss of function of DLL4 results in VEGF upregulation, and the formation of immature vessels without a lumen. It has been shown that DLL4 inhibition can actually result in tumor regression by its role on VEGF upregulation. DLL4 is found in several tumor types, and it is found in tumor stem cells. Inhibition of DLL4 can thus contribute to cancer therapy via its several mechanisms of action.
Description: Recombinant human DLL4 (delta-like canonical Notch ligand 4), encompassing amino acids 27-529. This construct contains the Fc region of human IgG1 on the C-terminus, followed by an Avi-Tag™. This protein was affinity purified.
Format: Aqueous buffer solution.
Formulation: 8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
Genbank: NM_019074.4
Host Cell Line: HEK293
Purity: ≥90%
Storage Stability: At least 6 months at -80°C.
Tags: C-terminal Avi-Tag™
Uniprot: Q9NR61
Warnings: Avoid freeze/thaw cycles
Biosafety Level: Not applicable (BSL-1)
| Artikelnummer | BPS101903-1 |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 101903-1 |
| Green Labware | Nein |
| Verpackungseinheit | 10 µg |
| Mengeneinheit | STK |
| Methode | ELISA |
| Wirt | Human |
| Produktinformation (PDF) | Download |
| MSDS (PDF) |
|
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
